RÉSUMÉ
Cancer therapy, including immunotherapy, is inherently limited by chronic inflammation-induced tumorigenesis and toxicity within the tumor microenvironment. Thus, stimulating the resolution of inflammation may enhance immunotherapy and improve the toxicity of immune checkpoint inhibition (ICI). As epoxy-fatty acids (EpFAs) are degraded by the enzyme soluble epoxide hydrolase (sEH), the inhibition of sEH increases endogenous EpFA levels to promote the resolution of cancer-associated inflammation. Here, we demonstrate that systemic treatment with ICI induces sEH expression in multiple murine cancer models. Dietary omega-3 polyunsaturated fatty acid supplementation and pharmacologic sEH inhibition, both alone and in combination, significantly enhance anti-tumor activity of ICI in these models. Notably, pharmacological abrogation of the sEH pathway alone or in combination with ICI counter-regulates an ICI-induced pro-inflammatory and pro-tumorigenic cytokine storm. Thus, modulating endogenous EpFA levels through dietary supplementation or sEH inhibition may represent a unique strategy to enhance the anti-tumor activity of paradigm cancer therapies.
Sujet(s)
Epoxide hydrolase , Tumeurs , Souris , Humains , Animaux , Epoxide hydrolase/métabolisme , Acides gras/métabolisme , Inflammation/métabolisme , Tumeurs/thérapie , Immunothérapie , Microenvironnement tumoralRÉSUMÉ
BACKGROUND: Cancer is a major burden of disease worldwide and increasing evidence shows that inflammation contributes to cancer development and progression. Eicosanoids are derived from dietary polyunsaturated fatty acids, such as arachidonic acid (AA), and are mainly produced by a series of enzymatic pathways that include cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P-450 epoxygenase (CYP). Eicosanoids consist of at least several hundred individual molecules and play important roles in the inflammatory response and inflammation-related cancers. SCOPE AND APPROACH: Dietary sources of AA and biosynthesis of eicosanoids from AA through different metabolic pathways are summarized. The bioactivities of eicosanoids and their potential molecular mechanisms on inflammation and cancer are revealed. Additionally, current challenges and limitations in eicosanoid research on inflammation-related cancer are discussed. KEY FINDINGS AND CONCLUSIONS: Dietary AA generates a large variety of eicosanoids, including prostaglandins, thromboxane A2, leukotrienes, cysteinyl leukotrienes, lipoxins, hydroxyeicosatetraenoic acids (HETEs), and epoxyeicosatrienoic acids (EETs). Eicosanoids exert different bioactivities and mechanisms involved in the inflammation and related cancer developments. A deeper understanding of eicosanoid biology may be advantageous in cancer treatment and help to define cellular targets for further therapeutic development.
Sujet(s)
Éicosanoïdes , Tumeurs , Humains , Éicosanoïdes/métabolisme , Acide arachidonique/métabolisme , Tumeurs/métabolisme , Leucotriènes , Inflammation/métabolisme , Cyclooxygenase 2RÉSUMÉ
Oral delivery is the most convenient way to vaccinate cultured fish, however it is still problematic, primarily due to a lack of a commercially valid vaccine vehicle to protect the antigen against gastric degradation and ensure its uptake from the intestine. With the goal of advancing the potential to vaccinate orally, this study evaluates a novel silicon nanoparticle-based vehicle (VacSaf carrier). Aeromonas salmonicida antigens were formulated with the VacSaf carrier using different preparation methods to generate dry powder and liquid formulations. Twelve formulations were first subjected to an in vitro evaluation where the A. salmonicida bacterin conjugated to VacSaf carriers were found superior at inducing pro-inflammatory cytokine expression in primary leucocyte cultures and the macrophage/monocyte cell line RTS-11 compared with A. salmonicida bacterin alone. This was especially apparent after exposure to acid conditions to mimic stomach processing. One formulation (FD1) was taken forward to oral delivery using two doses and two administration schedules (5 days vs 10 days, the latter 5 days on, 5 days off, 5 days on), and the transcript changes of immune genes in the intestine (pyloric caeca, midgut and hindgut) and spleen were evaluated by qPCR and serum IgM was measured by ELISA. The VacSaf carrier alone was shown to be safe for use in vivo, in that no side-effects were seen, but it did induce expression of some cytokines, and may have value as an oral adjuvant candidate. The FD1 bacterin formulation was effective at inducing a range of cytokines associated with innate and adaptive immunity, mainly in the pyloric caeca, compared to A. salmonicida bacterin alone (which had almost no effect), and confirms the immune competence of this gut region following appropriate oral vaccination. These results reveal that in vitro screening of formulations for oral delivery has value and can be used to assess the most promising formulations to test further.
Sujet(s)
Aeromonas salmonicida/immunologie , Vaccins antibactériens/immunologie , Maladies des poissons/immunologie , Nanoparticules/administration et posologie , Oncorhynchus mykiss/immunologie , Vaccination/médecine vétérinaire , Immunité acquise , Adjuvants immunologiques/administration et posologie , Administration par voie orale , Animaux , Antigènes bactériens/immunologie , Vaccins antibactériens/administration et posologie , Lignée cellulaire , Systèmes de délivrance de médicaments/instrumentation , Systèmes de délivrance de médicaments/méthodes , Systèmes de délivrance de médicaments/médecine vétérinaire , Infections bactériennes à Gram négatif/immunologie , Infections bactériennes à Gram négatif/médecine vétérinaire , Immunité innée , Macrophages/immunologie , Monocytes/immunologie , Vaccination/instrumentation , Vaccination/méthodesRÉSUMÉ
The teleost gut is a multifunction complex structure that plays a pivotal immunological role in homeostasis and the maintenance of health, in addition to digestion of food and/or nutrient absorption. In vitro examination of the intestine leucocyte repertoire has the potential to aid our understanding of gut immune competence and allows a rapid screen of host-microorganism interactions in different immunological contexts. To explore this possibility, in the present study we investigated the response of isolated gut leucocytes to 4 bacterins of Aeromonas salmonicida, prepared from different strains, combinations and strains grown in different environments, in comparison to a Yersinia ruckeri bacterin for which a commercial/effective oral booster vaccine has been developed. To aid this study we also optimized further our method of GALT cell isolation from rainbow trout, so as to avoid mechanical clearance of the intestine contents. This drastically increased the cell yield from ~12 × 106 to ~210 × 106/fish with no change in the percent cell viability over time or presence of transcripts typical of the key leucocyte types needed for the study of immune modulation (i.e. T- and B-cells, dendritic cells and macrophages). A wide array of immune transcripts were modulated by the bacterins, demonstrating the diversity of GALT cell responses to bacterial stimulation. Indeed, the GALT leucocyte responses were sensitive enough to distinguish the different bacterial species, strains and membrane proteins, as seen by distinct kinetics of immune gene expression. However, the response of the GALT cells was often relatively slow and of a low magnitude compared to those of PBL. These results enhance our knowledge of the gut biocapacity and help validate the use of this model for screening of oral vaccine candidates.
Sujet(s)
Aeromonas salmonicida/physiologie , Vaccins antibactériens/administration et posologie , Immunité innée/génétique , Tissu lymphoïde/immunologie , Oncorhynchus mykiss/immunologie , Yersinia ruckeri/physiologie , Animaux , Intestins/immunologie , Leucocytes/immunologieRÉSUMÉ
Fish aquaculture is the world's fastest growing food production industry and infectious diseases are a major limiting factor. Vaccination is the most appropriate method for controlling infectious diseases and a key reason for the success of salmonid cultivation and has reduced the use of antibiotics. The development of fish vaccines requires the use of a great number of experimental animals that are challenged with virulent pathogens. In vitro cell culture systems have the potential to replace in vivo pathogen exposure for initial screening and testing of novel vaccine candidates/preparations, and for batch potency and safety tests. PBL contain major immune cells that enable the detection of both innate and adaptive immune responses in vitro. Fish PBL can be easily prepared using a hypotonic method and is the only way to obtain large numbers of immune cells non-lethally. Distinct gene expression profiles of innate and adaptive immunity have been observed between bacterins prepared from different bacterial species, as well as from different strains or culturing conditions of the same bacterial species. Distinct immune pathways are activated by pathogens or vaccines in vivo that can be detected in PBL in vitro. Immune gene expression in PBL after stimulation with vaccine candidates may shed light on the immune pathways involved that lead to vaccine-mediated protection. This study suggests that PBL are a suitable platform for initial screening of vaccine candidates, for evaluation of vaccine-induced immune responses, and a cheap alternative for potency testing to reduce animal use in aquaculture vaccine development.
Sujet(s)
Aquaculture/méthodes , Vaccins antibactériens/immunologie , Maladies des poissons/prévention et contrôle , Expression des gènes/immunologie , Infections bactériennes à Gram négatif/médecine vétérinaire , Oncorhynchus mykiss/génétique , Oncorhynchus mykiss/immunologie , Aeromonas salmonicida/immunologie , Animaux , Vaccins antibactériens/administration et posologie , Maladies des poissons/immunologie , Infections bactériennes à Gram négatif/immunologie , Infections bactériennes à Gram négatif/prévention et contrôle , Techniques in vitro/méthodes , Leucocytes/immunologie , Yersinia ruckeri/immunologieRÉSUMÉ
UNLABELLED: The aim of our study was to report the status of penile cancer sites in the urology department at the University Hospital of Rabat and evaluate long-term results of surgical treatment of this cancer. PATIENTS AND METHODS: Between 1989 and 2015, 10 patients were treated for penile cancer. 10 cases were retrospectively reviewed and the following data were recorded: mode of revelation, seat, staging, TNM stage, treatment, evolution and survival. The mean age of patients was 58,1 years (48-81 years). All patients had squamous cell carcinoma of the penis. Six patients had a partial amputation of the penis, and three patients underwent total amputation. The median size of the lesion was 4.25 cm (1.5-8 cm). All tumors had a distal seat (gland- Furrow balanopreputial), 8 were localized and non-invasive (PT1 - PT2) and 2 had infiltrated the urethra (PT3). Four patients had lymph node localization. A single bilateral lymphadenectomy was performed and was positive only on one side, with a node <3 cm and no extracapsular extension. Two patients were referred for chemotherapy, a neoadjuvant referred to basic (Bleomycin - Methotrexate, Cisplatin) the other in a palliative goal. Median follow-up was 42 months (6 -72mois). Four patients died, one of which was presented immediately with metastatic mode. Six patients were alive at last node or local recurrence negative. Cancer of the penis seems rare in Morocco. His oncologic and functional outcomes (sexual and urinary) depend on the precocity of the treatment. The surgery of lymph node resection with lymphadenectomy remains the reference treatment.
Sujet(s)
Carcinome épidermoïde/anatomopathologie , Lymphadénectomie/méthodes , Tumeurs du pénis/anatomopathologie , Sujet âgé , Sujet âgé de 80 ans ou plus , Antinéoplasiques/administration et posologie , Carcinome épidermoïde/épidémiologie , Carcinome épidermoïde/chirurgie , Études de suivi , Hôpitaux universitaires , Humains , Mâle , Adulte d'âge moyen , Maroc/épidémiologie , Traitement néoadjuvant/méthodes , Tumeurs du pénis/épidémiologie , Tumeurs du pénis/chirurgie , Études rétrospectivesRÉSUMÉ
Leiomyoma is a benign smooth muscle tumor which is rarely found in urethra. It often appears in females during their reproductive age (from menarche to menopause); the mean age of their appearance is approximately 41 years. Less than 100 cases were reported in the literature. We hereby report a case of a 52-year-old White woman who presented with complaints of dysuria and urinary tract infection. The mass was completely removed by transvaginal excision with a rim of normal tissue. Histopathological studies confirmed the urethral leiomyoma. The patient remained asymptomatic and there was no evidence of recurrence in the followup.
Sujet(s)
Léiomyome/anatomopathologie , Tumeurs de l'urètre/anatomopathologie , Dysurie/étiologie , Femelle , Études de suivi , Humains , Léiomyome/diagnostic , Léiomyome/chirurgie , Adulte d'âge moyen , Tumeurs de l'urètre/diagnostic , Tumeurs de l'urètre/chirurgie , Infections urinaires/étiologieRÉSUMÉ
The aim of vaginoplasty should be the creation without excessive morbidity of a neovagina that will be satisfying in appearance, function and feeling. The multitude of methods described in the literature indicates the fact that an ideal approach has not yet been found. In this paper the authors describe the technique for repairing vaginal stenosis by interposing between the vaginal walls, a skin flap pedicled removed using the Falandry technique at a high lip. We achieved a satisfactory result.